instructions [400:<2 weeks and generally does not require dosage reduction or contraindicate use of the drug. 1 If delavirdine therapy is interrupted because of rash, most patients are able to resume therapy with the drug. 1 Mild or moderate rash can be treated with diphenhydramine hydrochloride, hydroxyzine hydrochloride, and/or topical corticosteroids. 1 General Precautions HIV Resistance Possibility of HIV resistant to delavirdine and possible cross-resistance to other NNRTIs. 1 Adipogenic Effects Redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement ( buffalo hump ), peripheral wasting, facial wasting, breast enlargement, and general cushingoid appearance reported in patients receiving antiretroviral therapy. 1 Mechanisms and long-term consequences unknown; causal relationship not established. 1 Immune Reconstitution Syndrome During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium complex [MAC], M. tuberculosis , cytomegalovirus [CMV], Pneumocystis jirovecii [formerly P. carinii ]); this may necessitate further evaluation and treatment. 1 Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) have been reported to occur in the setting of immune reconstitution; time to onset is variable and can occur many months after initiation of antiretroviral therapy. 1 Specific Populations Pregnancy Category C. 1 Antiretroviral Pregnancy Registry at 800-258-4263 or . 1 202 Lactation Distributed into milk in rats; not known whether distributed into human milk. 1 Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant. 1 202 Pediatric Use Safety and efficacy not established in children> <16 years of age. 1 Geriatric Use Insufficient experience in those 65 years of age to determine whether they respond differently than younger adults. 1 Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy. 1 Hepatic Impairment Extensively metabolized in liver; use with caution in those with hepatic impairment. 1 Common Adverse Effects Rash, asthenia/fatigue, nausea. 1 Interactions for Delavirdine Mesylate Metabolized by CYP3A and CYP2D6. 1 Inhibits CYP3A and, to a lesser extent, 2C9, 2D6, and 2C19. 1 Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes Pharmacokinetic interactions likely with drugs that are inhibitors, inducers, or substrates of CYP3A; 1 possible alteration in metabolism of delavirdine and/or other drug. 1 Specific Drugs Drug Interaction Comments Amphetamines Possible increased amphetamine concentrations 1 Use with caution 1 Antacids, aluminum- or magnesium-containing Decreased delavirdine concentrations 1 Take delavirdine at least 1 hour before or after antacids 1 Antiarrhythmic agents (amiodarone, flecainide, systemic lidocaine, propafenone, quinidine) Possible increased concentrations of antiarrhythmic agent; potential for serious or life-threatening effects (e.g., cardiac arrhythmias) with certain agents 1 Use concomitantly with caution; monitor plasma concentrations of antiarrhythmic agent 1 Anticoagulants, oral Possible increased warfarin concentrations 1 Monitor INR; adjust warfarin dosage accordingly 1 Anticonvulsants (carbamazepine, phenytoin, phenobarbital) Decreased delavirdine concentrations; possible loss of virologic response and development of resistance to the antiretroviral and other NNRTIs 1 Do not use concomitantly with delavirdine 1 Antifungals, azoles (fluconazole, ketoconazole, voriconazole) Fluconazole: Pharmacokinetic interaction not clinically important 1 Ketoconazole: Increased delavirdine concentrations 1 Voriconazole: Increased voriconazole concentrations 53 Voriconazole: Monitor frequently for voriconazole adverse effects 53 Antimycobacterials (rifabutin, rifampin, rifapentine) Rifabutin: Decreased delavirdine AUC; increased rifabutin AUC 1 Rifampin: Decreased delavirdine AUC 1 Possible loss of virologic response and increased risk of delavirdine or NNRTI resistance 1 Concomitant use with rifabutin, rifampin, or rifapentine not recommended 1 34 35 200 Atazanavir No in vitro evidence of antagonistic antiretroviral effects 203 Benzodiazepines (alprazolam, midazolam, triazolam) Potential for serious and/or life-threatening adverse effects such as prolonged or increased sedation or respiratory depression 1 Concomitant use contraindicated 1 Calcium-channel blocking agents (amlodipine, diltiazem, felodipine, isradipine, nifedipine, nimodipine, nisoldipine, verapamil) Possible increased concentrations of calcium-channel blocking agent 1 Use concomitantly with caution; clinical monitoring recommended 1 Cisapride Potential for serious or life-threatening reactions (e.g., cardiac arrhythmias) 1 Concomitant use contraindicated 1 Co-trimoxazole Interaction unlikely 1 Corticosteroids (dexamethasone, fluticasone) Dexamethasone: Possible decreased delavirdine concentrations 1 Dexamethasone: Use with caution; delavirdine may be less effective 1 Fluticasone (orally inhaled, intranasal): Possible increased fluticasone concentrations 1 Fluticasone (orally inhaled, intranasal): Use concomitantly with caution; consider alternative to fluticasone, especially when long-term corticosteroid therapy is anticipated 1 Darunavir No in vitro evidence of antagonistic antiretroviral effects 204 Didanosine Decreased delavirdine concentrations if given at same time as buffered didanosine preparations; 1 clinically important pharmacokinetic interaction not observed when buffered didanosine administered 1 hour after delavirdine 1 In vitro evidence of additive to synergistic antiretroviral effects 1 Administer buffered didanosine (pediatric oral solution admixed with antacid) at least 1 hour before or after delavirdine 1 Efavirenz Do not use concomitantly 1 200 Emtricitabine In vitro evidence of additive or synergistic antiretroviral effects 218 Ergot alkaloids (dihydroergotamine, ergonovine, ergotamine, methylergonovine) Concomitant use contraindicated 1 Estrogens/Progestins Hormonal contraceptives: Possible increased concentrations of ethinyl estradiol 1 Clinical importance unknown 1 Etravirine Possible increased etravirine concentrations 214 Do not use concomitantly 1 200 214 Fluoxetine Increased delavirdine trough concentrations 1 Fosamprenavir Studies using amprenavir (active metabolite of fosamprenavir) indicate increased amprenavir concentrations and AUC and possible decreased delavirdine concentrations and AUC; 205 possible decreased antiretroviral efficacy and increased risk of antiretroviral resistance 205 In vitro evidence of synergistic antiretroviral effects 205 Fosamprenavir (with or without low-dose ritonavir): Concomitant use contraindicated 205 Histamine H 2 -receptor antagonists (cimetidine, famotidine, nizatidine, ranitidine) Possible decreased GI absorption of delavirdine 1 Long-term concomitant use not recommended 1 HMG-CoA reductase inhibitors (statins) Atorvastatin, fluvastatin, lovastatin, simvastatin: Possible increased concentrations of the antilipemic agents; increased risk of myopathy and/or rhabdomyolysis 1 Atorvastatin: Use lowest possible atorvastatin dosage; 1 consider using pravastatin instead 1 Fluvastatin: Use lowest possible fluvastatin dosage; 1 consider using pravastatin instead 1 Lovastatin: Do not use concomitantly 1 Simvastatin: Do not use concomitantly 1 Immunosuppressive agents (cyclosporine, sirolimus, tacrolimus) Potential for increased concentrations of cyclosporine, sirolimus, or tacrolimus 1 Monitor plasma concentrations of immunosuppressive agent 1 Indinavir Delavirdine inhibits indinavir metabolism and may increase indinavir concentrations and AUC; no effect on delavirdine pharmacokinetics 1 206 Use reduced indinavir dosage of 600 mg every 8 hours with usual delavirdine dosage (400 mg 3 times daily) 1 206 Lamivudine In vitro evidence of additive or synergistic antiretroviral effects 1 Lopinavir/ritonavir Possible increased lopinavir concentrations 1 Appropriate dosages for concomitant use with respect to safety and efficacy not established 1 Macrolides (clarithromycin) No change in delavirdine pharmacokinetic; increased clarithromycin AUC 1 Dosage adjustments not needed in patients with normal renal function; reduce clarithromycin dosage by 50% in patients with Cl cr 30 60 mL/minute and by 75% in patients with Cl cr> <30 mL/minute 1 Maraviroc Possible increased maraviroc concentrations 1 No in vitro evidence of antagonistic antiretroviral effects 224 Recommended maraviroc dosage is 150 mg twice daily in patients receiving delavirdine 224 Methadone Possible increased methadone concentrations 1 Methadone dosage may need to be reduced 1 Nelfinavir Decreased delavirdine concentrations and AUC; increased nelfinavir concentrations and AUC 1 208 In vitro evidence of synergistic antiretroviral effects 208 Appropriate dosages for concomitant use with respect to safety and efficacy not established 1 208 Nevirapine Do not use concomitantly 1 200 Pimozide Potential for serious or life-threatening reactions (e.g., cardiac arrhythmias) 1 Concomitant use contraindicated 1 Proton-pump inhibitors (omeprazole, lansoprazole) Possible decreased GI absorption of delavirdine 1 Long-term concomitant use not recommended 1 Quinupristin and dalfopristin Possible increased delavirdine concentrations 39 Raltegravir In vitro evidence of additive to synergistic antiretroviral effects 225 Rilpivirine Possible increased rilpivirine concentrations 226 Do not use concomitantly 1 200 226 Ritonavir Increased ritonavir concentrations 1 Appropriate dosages for concomitant use with respect to safety, efficacy, and pharmacokinetics not established 1 Saquinavir Increased saquinavir concentrations and AUC; 1 210 no clinically important effect on delavirdine concentrations 1 Ritonavir-boosted saquinavir: Concomitant use not evaluated 210 Appropriate dosages for concomitant use with respect to safety, efficacy, and pharmacokinetics not established 1 210 Simeprevir Possible increased simeprevir concentrations 187 Concomitant use not recommended 187 St. John s wort ( Hypericum perforatum ) Possible loss of virologic response and increased risk of delavirdine or NNRTI resistance 1 Do not use concomitantly 1 Sildenafil Possible increased sildenafil concentrations and increased risk of sildenafil-associated adverse effects (e.g., hypotension, visual changes, prolonged erection) 1 Use caution; do not exceed 25 mg once every 48 hours 1 Tenofovir No in vitro evidence of antagonistic antiretroviral effects 221 Tipranavir In vitro evidence of additive antiretroviral effects 211 Trazodone Possible increased trazodone concentrations 1 Adverse effects (nausea, dizziness, hypotension, syncope) reported with concomitant use of trazodone and other CYP3A inhibitors (e.g., ritonavir) 1 Use with caution; consider using decreased trazodone dosage 1 Zidovudine No pharmacokinetic interaction 1 6 In vitro evidence of additive or synergistic antiretroviral effects 1 Delavirdine Mesylate Pharmacokinetics Absorption Bioavailability Rapidly absorbed from GI tract; peak plasma concentrations achieved within 1 hour. 1 Bioavailability of delavirdine tablets is 85% relative to that of an oral solution of the drug. 1 Bioavailability of 100-mg tablets is increased by approximately 20% when allowed to disintegrate in water and administered as a slurry. 1 Food Food does not have an appreciable effect on plasma concentrations or AUC. 1 Distribution Extent Not fully characterized. 1 Distributed into CSF in low concentrations. 1 Distributed into milk in rats; not known whether distributed into human milk. 1 Plasma Protein Binding 98%. 1 Elimination Metabolism Metabolized by CYP3A and CYP2D6. 1 Elimination Route Excreted in feces (44%) and urine (51%). 1 Half-life 5.8 hours. 1 Stability Storage Oral Tablets 20 25 C in tight container; protect from high humidity. 1 Actions and Spectrum Pharmacologically related to other NNRTIs (e.g., efavirenz, etravirine, nevirapine, rilpivirine); differs structurally from these drugs; also differs pharmacologically and structurally from other currently available antiretrovirals. 1 6 7 8 10 11 12 214 Active against HIV-1; inactive against HIV-2. 1 8 31 Inhibits replication of HIV-1 by interfering with viral RNA- and DNA-directed polymerase activities of reverse transcriptase. 1 6 7 8 10 11 12 15 HIV-1 with reduced susceptibility to delavirdine have been selected in vitro and have emerged during therapy with the drug. 1 6 8 19 31 Strains of HIV-1 resistant to delavirdine may be cross-resistant to some other NNRTIs. 1 6 7 Cross-resistance between delavirdine and NRTIs unlikely since the drugs bind at difference sites on reverse transcriptase and have different mechanisms of action. 1 15 Cross-resistance between delavirdine and HIV protease inhibitors (PIs) unlikely since the drugs have different target enzymes and mechanisms of action. 1 Advice to Patients Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician. 1 Importance of taking as prescribed; do not alter or discontinue antiretroviral regimen without consulting clinician. 1 Importance of using in conjunction with other antiretrovirals not for monotherapy. 1 Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur. 1 Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others. 200 Importance of continuing to practice safer sex (e.g., using latex or polyurethane condoms to minimize sexual contact with body fluids), never sharing personal items that can have blood or body fluids on them (e.g., toothbrushes, razor blades), and never reusing or sharing needles. 1 200 Importance of reading patient information provided by the manufacturer. 1 Importance of patients with achlorhydria taking delavirdine with an acidic beverage. 1 If a dose is missed, the next dose should be taken as soon as possible. 1 If a dose is skipped, do not take a double dose to make up for the missed dose. 1 Importance of discontinuing delavirdine and consulting a clinician if severe rash or rash accompanied by fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches occurs. 1 Redistribution/accumulation of body fat may occur, with as yet unknown long-term health effects. 1 Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products (e.g., St. John s wort), and any concomitant illnesses. 1 Advise patients receiving PDE5 inhibitors (e.g., sildenafil) that they may be at increased risk of PDE5 inhibitor-associated adverse effects (e.g., hypotension, visual disturbances, priapism) and that any symptoms should be promptly reported to their clinician. 1 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 1 Advise HIV-infected women not to breast-feed. 1 Importance of advising patients of other important precautionary information. 1 (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Delavirdine Mesylate Routes Dosage Forms Strengths Brand Names Manufacturer Oral Tablets 100 mg Rescriptor ViiV 200 mg Rescriptor ViiV AHFS DI Essentials. Copyright 2017, Selected Revisions February 12, 2015. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. ViiV Healthcare. Rescriptor (delavirdine mesylate) tablets prescribing information. Research Triangle Park, NC; 2012 Aug. 5. Friedland GH, Pollard R, Griffith B et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease and CD4 counts of 100 to 500 cells/mm 3 (ACTG 261). J Acquir Immune Defic Syndr . 1999; 21:281-92. [PubMed 10428106] 6. Pharmacia & Upjohn, Kalamazoo, MI: Personal communication. 7. Moyle GJ. Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunol Infect Dis . 1995; 5:170-82. 8. Freimuth WW. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chemother . 1996; 4:279-89. 9. Dueweke TJ, Poppe SM, Romero DL et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother . 1993; 37:1127-31. [PubMed 7685995] 10. Althaus IW, Chou JJ, Gonzales AJ et al. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem . 1993; 268:6119-24. [PubMed 7681060] 11. Althaus IW, Chou JJ, Gonzales AJ et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol . 1994; 47:2017-28. [PubMed 7516658] 12. Dueweke TJ, Kezdy FJ, Waszak GA et al. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem . 1992; 267:27-30. [PubMed 1370445] 13. Watkins BA, Klotman ME, Gallo RC. Human Immunodeficiency Viruses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:1590-606. 14. Sardana VV, Emini EA, Gotlib L et al. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem . 1992; 267:17526-30. [PubMed 1381350] 15. Gu Z, Quan Y, Li Z et al. Effects of nonnucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. J Biol Chem . 1995; 270:31046-51. [PubMed 8537362] 16. Vasudevachari MB, Battista C, Lane HC et al. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology . 1992; 190:269-77. [PubMed 1382341] 18. Chong KT, Pagano PJ. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Res . 1997; 34:51-63. [PubMed 9107385] 19. Demeter LM, Meehan PM, Morse G et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr . 1997; 14:136-44. 20. Kohlstaedt LA, Wang J, Friedman JM et al. Crystal structure at 3.5 resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science . 1992; 256:1783-90. [PubMed 1377403] 21. Spence RA, Kati WM, Anderson KS et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science . 1995; 267:988-93. [PubMed 7532321] 26. AIDS Clinical Trials Information Service (ACTIS) (database). 2000 Jun. From web site. 27. Barin F, Couroue AM, Pillonel J et al. Increasing diversity of HIV-1 M serotypes in French blood donors over a 10-year period (1985-1995). AIDS . 1997; 11:1503-8. [PubMed 9342073] 30. Reviewers comments (personal observations). 31. Witvrouw M, Pannecourque C, Van Laethem K et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS . 1999; 13:1477-83. [PubMed 10465070] 33. Rohrs BR, Thamann TJ, Gao P et al. Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrant. Pharm Res . 1999; 16:1850-6. [PubMed 10644073] 34. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations MMWR . 1998; 47(No. RR-20). 35. Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep . 2000; 49:185-9. [PubMed 11795500] 36. Borin MT, Cox SR, Herman BD et al. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrob Agents Chemother . 1997; 41:1892-7. [PubMed 9303380] 37. Demeter LM, Shafer RW, Meehan PM et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother . 2000; 44:794-7. [PubMed 10681363] 38. Mills G, Morgan J, hales G et al. Acute hypersensitivity with delavirdine. Antivir Ther . 1999; 4:51. [PubMed 10682129] 39. Rhone-Poulenc Rorer Pharmaceuticals Inc. Synercid I.V. (quinupristin and dalfopristin) prescribing information. Collegeville, PA; 1999 Jul. 40. Lumpkin MM, Alpert A. Risk of drug interactions with St. John s wort and indinavir and other drugs. FDA Public Health Advisory. 2000 Feb 10. From FDA website. 41. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St. John s wort. Lancet . 2000; 355:547-8. [PubMed 10683007] 42. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John s wort ( Hypericum perforatum ). Clin Pharmacol Ther . 1999; 66:338-45. [PubMed 10546917] 43. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John s wort. Lancet . 2000; 355:548-9. [PubMed 10683008] 45. Yuen N (Agouron Pharmaceuticals, La Jolla, CA). Personal communication; 2000 Aug 4. 47. American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infections. Am J Respir Crit Care Med . 2000; 161:S221-47. 49. Hood R, Hawkins DA, Moyle G et al. Second placebo-controlled study in naive individuals confirms the role of delavirdine in highly active antiretroviral, protease-sparing treatment. Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1999. 50. Moyle G, De Cian W, Hawkins D et al. Final 54-week analysis of a placebo-controlled trial (13C) of delavirdine (DLV) plus two nucleoside analogs (NA) versus two NA in drug-naïve and -experienced individuals. Proceedings of the 39th ICAAC. San Francisco, CA: 1999. 52. Smith D, Hales G, Roth N et al. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clin Trials . 2001; 2:97-107. [PubMed 11590517] 53. Pfizer. Vfend (voriconazole) for injection, tablets, and for oral suspension prescribing information. New York, NY; 2011 Nov. 187. Janssen. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2013 Nov. 200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 1, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website. 202. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States (March 28, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website. 203. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules and oral powder prescribing information. Princeton, NJ; 2014 Jun. 204. Janssen. Prezista (darunavir) oral suspension and tablets prescribing information. Titusville, NJ; 2014 Apr. 205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2013 Apr. 206. Merck Sharp & Dohme. Crixivan (indinavir sulfate) capsules prescribing information. Whitehouse Station, NJ; 2014 Jul. 208. ViiV Healthcare. Viracept (nelfinavir mesylate) tablets and oral powder prescribing information. Research Triangle Park, NC; 2012 Apr. 210. Genentech USA. Invirase (saquinavir mesylate) capsules and tablets prescribing information. South San Francisco, CA; 2012 Nov. 211. Boehringer Ingelheim. Aptivus (tipranavir) capsules and oral solution prescribing information. Ridgefield, CT; 2012 Apr. 214. Janssen. Intelence (etravirine) tablets prescribing information. Raritan, NJ; 2012 Mar. 218. Gilead Sciences. Emtriva (emtricitabine) capsules and oral solution prescribing information. Foster City, CA; 2012 Jul. 221. Gilead Sciences. Viread (tenofovir disoproxil fumarate) tablets prescribing information. Foster City, CA; 2013 Oct. 224. ViiV Healthcare. Selzentry (maraviroc) tablets prescribing information. Research Triangle Park, NC; 2014 Mar. 225. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets, chewable tablets, and for oral suspension prescribing information. Whitehouse Station, NJ; 2014 Apr. 226. Janssen Therapeutics. Edurant (rilpivirine) tablets prescribing information. Titusville, NJ; 2014 May. Next Interactions Print this page Add to My Med List More about delavirdine Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: NNRTIs Consumer resources Delavirdine Delavirdine (Advanced Reading) Professional resources Delavirdine (Wolters Kluwer) Other brands: Rescriptor Related treatment guides HIV Infection> ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class NNRTIs Related Drugs HIV Infection Truvada , Atripla , Norvir , Viread , Isentress , Prezista , Stribild , lamivudine , abacavir , tenofovir , Reyataz , Epzicom , ritonavir , Complera , emtricitabine , darunavir , Kaletra , Intelence , Sustiva , Epivir , efavirenz , nevirapine , atazanavir , raltegravir , Selzentry , More... Delavirdine Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } maintaining
that kids Delavirdine Mesylate sales space
EmoticonEmoticon